Cost analysis of flavocoxid compared to naproxen for management of mild to moderate OA

GOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin

(2010) Lakshmi Pillai et al.   CURRENT MEDICAL RESEARCH AND OPINION

Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages

(2009) D Altavilla et al.   BRITISH JOURNAL OF PHARMACOLOGY

Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, double-blind pilot study

(2009) Robert M. Levy et al.   NUTRITION RESEARCH

Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease

(2009) Christianne L. Roumie et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines

(2008) W. Zhang et al.   OSTEOARTHRITIS AND CARTILAGE

Care and management of osteoarthritis in adults: summary of NICE guidance

(2008) Philip G Conaghan et al.   BMJ-British Medical Journal